GSK submits lupus drug for EU approval

06/7/2010 | Reuters

GlaxoSmithKline submitted a marketing application to the European Medicines Agency for its lupus drug candidate Benlysta. The drugmaker, which co-develops Benlysta with Human Genome Sciences, also plans to file for FDA approval of the treatment later this month.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC